

Supplementary figures for

**Somatic Functional Deletions of Upstream Open Reading  
Frame-Associated Initiation and Termination Codons in  
Human Cancer**

Lara Jürgens, Felix Manske, Elvira Hubert, Tabea Kischka, Lea Flötotto, Oliver Klaas, Victoria Shabardina, Christoph Schliemann, Wojciech Makalowski and Klaus Wethmar

**Table S1: Sequences of TLSs selected for experimental analysis.**

TLS sequences commercially synthesized (GeneArt®, Invitrogen) for dual luciferase reporter assays. The variant codon affected by individual SNVs is underlined, written in bold letters, and displayed in wild type/mutant configuration. The CDS start codon is written in capital letters.

[illegible]

**Table S2: List of oligonucleotides used for SDM of initiation and termination codons.**

All forward and reverse oligonucleotides (primers) used for site directed mutagenesis (SDM) are given in 5'-3'-sequence direction. The variant codons are written in bold capital letters, with mutated base underlined.

Induced SNV	RefSeq_ID	forward primer	reverse primer
BAGE2 ΔCUG.1	NM_182482.2	gcccgggggtct <b>CC</b> Ggtatctccgc	gcgggagatac <b>CG</b> Gagaccccggc
BAGE2 ΔUUG.1	NM_182482.2	gagaagggggag <b>CT</b> Ggaggtggag	ctccagctc <b>CAG</b> ctccccttctc
FANK1 ΔAGG.2/UAG.1	NM_145235.5	ctgagagcggt <b>TAC</b> Gagtcgggggttc	gaaccccgagct <b>CGT</b> Aacgctctcag
FRG2C ΔACG.2	NM_001124759.5	cccagccgaggg <b>AT</b> Gtataaaaggcag	ctgcttttata <b>CAT</b> ccctcggtggg
FRG2C ΔUAG.2	NM_001124759.5	gtataaaaggcaggtc <b>TG</b> Gcagactaaccacac	gtgtgggttagtctg <b>CCA</b> gactgctttatac
HLA-DRB1 ΔAUG.1/GUG.1	NM_002124.4	ctataacttga <b>ATAT</b> Ggtggaggggttc	gaacccctccacc <b>CATAT</b> tccaagttag
HLA-DRB1 ΔCUG.1	NM_002124.4	ggttcatagtctcc <b>CTC</b> agtgagacttgc	gcaagtctcact <b>GAG</b> ggagaactatgaacc
HLA-DRB1 ΔCUG.6	NM_002124.4	ctggtctctgc <b>CTG</b> ttctccagcatg	catgctggagaa <b>CAC</b> gacaggaccag
NDST3 ΔAUG.4	NM_004784.3	cttttt <b>ATT</b> gtctctgttggc	gccaacagaagcac <b>AAT</b> aaaaag
NDST3 ΔUAA.5	NM_004784.3	caccatctttctt <b>TAT</b> cttttatggtg	caccataaaaag <b>ATA</b> aaagaaaagatggtg
TMIGD3 ΔUUG.1	NM_001081976.2	ctagcgtggctg <b>CTG</b> gaagcttctg	cagaagcttc <b>CAC</b> cagccacgctag

**Table S3: Summary of SNVs with highest rates of entity-specific recurrence**

# = number. The average dbSNP frequency was calculated using individual frequencies according to the TopMed, ExAC, and GnomAD projects. If none of those contained variation data for individual SNVs "NONE" is displayed.

entity	most frequent uORF positions w/o dbSNP annotation				most frequent uORF positions with dbSNP annotation				
	gene	genomic position	effect	affected patients (%)	gene	genomic position	effect	affected patients (%)	dbSNP ID (average frequency, %)
BRCA	ROPN1	chr3:123980570	GUG>GGG; UGA>GGA	2.2	MELK	chr9: 36599396	UAA>GAA	8.6	rs374077047 (3.5)
	RABL2A	chr2:113628561	AUA>AUC	2.2					
COAD	OR2H1	chr6:29461656	AAG>GAG	1.6	SYNPR	chr3: 63443357	GUG>GGG	4.4	rs1183102673 (NONE)
LUAD	CBWD2	chr2:113437882	UUG>GUG	0.9	NBPF20	chr1: 145405250	UUG>UUU	3.3	rs1412188415 (0.01)
	POM121	chr7:72890655	GUG>GGG	0.9					
	MRGPRX4	chr11:18173175	GUG>GGG	0.9	ZNF7	chr8: 144829396	CUG>AUG	3.3	rs774406977 (0.1)
PRAD	VEZF1	chr17:57983388	UGA>AGA	2.0	CDC27	chr17: 47156984	AGG>AAG	4.6	rs772436784 (0.9)
SKCM	HMGXB4	chr22:35262339	ACG>ACU	2.5	CHCHD2	chr7: 56106490	AUC>AUU	8.1	rs867193277 (0.0008)
LAML	FDCSP	chr4:70234185	UAA>AAA	6.0	NBPF20	chr1: 145405250	UUG>UUU	10.1	rs1412188415 (0.01)

**Table S4: List of recurrent somatic SNVs observed in multiple types of cancer**

The average dbSNP frequency was calculated using individual frequencies according to the TopMed, ExAC, and GnomAD projects. If none of those contained variation data for individual SNVs “NONE” is displayed.

gene symbol ID	genomic position	variant	effect	entity (% of patients with somatic mutation)	dbSNP ID (average frequency, %)
AQP12B	chr2: 240682856	AUC>GUC	loss of aTIS	COAD (0.9); LUAD (0.9); PRAD (0.6); SKCM (0.6); BRCA (0.2)	rs760345459 (0.02)
AQP12B	chr2: 240682857	AUC>UUC	loss of aTIS	LUAD (0.9); COAD (0.7); PRAD (0.6); SKCM (0.4); BRCA (0.2)	rs766089521 (0.02)
BAGE; BAGE5; BAGE4	chr21: 10413594	UUG > CUG	aTIS>aTIS	SKCM (1.9); LUAD (1.6); BRCA (1.3); PRAD (0.8); COAD (0.7)	rs75318310 (NONE)
HLA-DRB1	chr6: 32589772	CUG > GUG	aTIS>aTIS	LUAD (0.5); COAD (0.5); BRCA (0.5); SKCM (0.4); PRAD (0.4)	rs17204744 (0.003)
TAS2R43	chr12: 11092279	AUU>ACU	loss of aTIS	COAD (0.9); BRCA (0.6); LUAD (0.5); SKCM (0.4); PRAD (0.4);	rs369719862 (0.3)
BAGE; BAGE5; BAGE4	chr21: 10413537	CUG>CCG	loss of aTIS	COAD (2.0); LUAD (1.4); LAML (1.3); BRCA (1.0); SKCM (0.9); PRAD (0.6)	rs78230864 (NONE)
CDC27	chr17: 47156984	AGG>AAG	aTIS>aTIS	PRAD (4.6); SKCM (2.3); LUAD (1.9); LAML (1.3); BRCA (1.1); COAD (0.7)	rs772436784 (0.9)
GRM5	chr11: 89047888	UGA>UUA; UUG>UUU	loss of uStop, loss of aTIS	BRCA (3.4); LAML (2.0); LUAD (1.6); COAD (0.9); SKCM (0.4); PRAD (0.4)	rs200235727 (1.2)
HLA-DRB5	chr6: 32530234	CUG>CUC	loss of aTIS	LAML (3.3); SKCM (2.3); BRCA (1.4); PRAD (1.0); LUAD (0.9); COAD (0.9)	rs3179203 (1.6)
LYZL2	chr10: 30629668	AAG>AGG; UAA>UAG	aTIS>aTIS; uStop>uStop	COAD (3.2); SKCM (2.8); LAML (2.0); PRAD (2.0); BRCA (1.8); LUAD (1.1)	rs74551644 (29.3)
LYZL2	chr10: 30629732	UUG>UUA	loss of aTIS	PRAD (2.8); SKCM (2.8); COAD (2.5); BRCA (2.5); LAML (2.0); LUAD (1.9)	rs777979230 (0.08)
MSANTD2	chr11: 124774825	UUG>UUU	loss of aTIS	LUAD (3.0); BRCA (2.3); LAML (2.0); PRAD (1.4); SKCM (0.9); COAD (0.5)	rs75374326 (6.6)
PRSS2	chr7: 142770963	AUC>GUC	loss of aTIS	COAD (2.7); LAML (2.7); BRCA (1.8); LUAD (0.9); SKCM (0.6); PRAD (0.4)	rs771586111 (NONE)
ST6GALNAC4	chr9: 127916493	GUG>GGG	loss of aTIS	BRCA (5.2); LUAD (1.6); LAML (1.3); COAD (1.2); PRAD (0.8); SKCM (0.6)	rs375089890 (NONE)
TAS2R43	chr12: 11092250	AUU>UUU	loss of aTIS	LAML (2.0); LUAD (1.4); PRAD (1.4); COAD (1.2); BRCA (1.2); SKCM (0.6)	rs779232783 (0.3)
TAS2R43	chr12: 11092256	UAA>UUA	loss of uStop	LAML (2.0); PRAD (1.4); LUAD (1.4); BRCA (1.2); COAD (1.2); SKCM (0.6)	rs748363493 (0.3)
TRMT1L	chr1: 185150477	UUG>UUU	loss of aTIS	LUAD (2.8); LAML (2.0); BRCA (1.4); SKCM (1.3); PRAD (1.2); COAD (0.5)	rs78652979 (4.8)